Alignment Healthcare (NASDAQ:ALHC) Reaches New 1-Year Low on Insider Selling

Alignment Healthcare, Inc. (NASDAQ:ALHC) shares hit a new 52-week low during trading on Wednesday following insider selling activity. The company traded as low as $9.94 and last traded at $10.37, with a volume of 28545880 shares changing hands. The stock had previously closed at $12.94.

Specifically, CEO John Kao sold 27,400 shares of Alignment Healthcare stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $13.00, for a total value of $356,200.00. Following the transaction, the chief executive officer owned 590,766 shares of the company’s stock, valued at $7,679,958. The trade was a 4.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Kao sold 385,270 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $12.68, for a total transaction of $4,885,223.60. Following the sale, the chief executive officer directly owned 1,223,473 shares of the company’s stock, valued at $15,513,637.64. The trade was a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In other Alignment Healthcare news, CEO John Kao sold 172,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $12.96, for a total value of $2,236,896.00. Following the completion of the sale, the chief executive officer directly owned 618,166 shares in the company, valued at $8,011,431.36. This trade represents a 21.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALHC. Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. TD Cowen reiterated a “buy” rating on shares of Alignment Healthcare in a report on Wednesday. Zacks Research cut Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Barclays dropped their target price on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Finally, Raymond James Financial lowered Alignment Healthcare from a “strong-buy” rating to an “outperform” rating and reduced their target price for the company from $22.00 to $19.00 in a research report on Monday, August 3rd. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Alignment Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.60.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Some analysts remain constructive after the selloff. Coverage continues to describe ALHC as a potential bargain, while brokerage ratings average “Moderate Buy.” The company’s latest reported quarter also showed revenue growth and an earnings beat, although those results predate the current concerns. Moderate Buy Analyst Rating
• Positive Sentiment: Unusual options activity and bullish analyst commentary suggest some investors are positioning for a rebound following the steep decline. However, these signals are speculative and do not resolve the company’s operating uncertainties. Bullish Analyst Commentary
• Neutral Sentiment: CEO John Kao sold 27,400 shares for approximately $356,200 under a pre-arranged Rule 10b5-1 trading plan. The planned nature of the transaction limits its significance as a direct bearish signal, though his ownership declined by 4.43%. SEC Insider Sale Filing
• Negative Sentiment: Management’s comments at the Baird conference, including limited visibility on Medicare Advantage star ratings, triggered investor concern. Star ratings can influence reimbursement and enrollment, making the lack of clarity a material risk to future growth and profitability. Alignment Healthcare Conference-Related Decline
• Negative Sentiment: Coverage also highlights proposed or potential Medicare Advantage reforms, increasing uncertainty about the company’s reimbursement environment and operating economics. Medicare Advantage Rule Changes
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations following the conference-related selloff. The notices do not establish wrongdoing, but they add potential legal, reputational and financial risk. Securities Fraud Investigation

Alignment Healthcare Stock Performance

The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 1.22. The company has a market cap of $1.80 billion, a PE ratio of 45.79 and a beta of 1.11. The firm’s 50-day simple moving average is $15.19 and its two-hundred day simple moving average is $17.75.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter last year, the company posted $0.07 earnings per share. The business’s quarterly revenue was up 31.6% on a year-over-year basis. As a group, research analysts anticipate that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alignment Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP grew its holdings in Alignment Healthcare by 8.9% in the fourth quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock valued at $137,000 after purchasing an additional 566 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Alignment Healthcare by 9.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 11,445 shares of the company’s stock worth $202,000 after buying an additional 962 shares during the period. GAMMA Investing LLC raised its stake in shares of Alignment Healthcare by 46.6% during the 2nd quarter. GAMMA Investing LLC now owns 3,368 shares of the company’s stock worth $80,000 after buying an additional 1,070 shares during the period. Versant Capital Management Inc lifted its position in shares of Alignment Healthcare by 463.3% during the 2nd quarter. Versant Capital Management Inc now owns 1,380 shares of the company’s stock valued at $33,000 after buying an additional 1,135 shares in the last quarter. Finally, Nykredit A S purchased a new position in shares of Alignment Healthcare during the 2nd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled healthcare company that provides Medicare Advantage health plans and care-management services for older adults. Through its Alignment Health Plan subsidiary, the company offers insurance coverage designed for Medicare-eligible members, including primary and specialty care coordination, prescription drug benefits, preventive services and access to a network of healthcare providers.

The company combines health-plan operations with proprietary technology intended to support personalized care.